Exagen Inc is primarily active in the healthcare and diagnostics industries.

The main competitors of Exagen Inc in the market include companies such as Myriad Genetics, Genomic Health, Veracyte, and Exact Sciences.

Exagen Inc is a leading biotechnology company specializing in the development and commercialization of innovative diagnostic tests. Founded in 2002, Exagen focuses on empowering patients and improving the quality of care through cutting-edge technologies. The company is dedicated to transforming the diagnosis and management of complex diseases by providing healthcare professionals with actionable insights based on advanced genomic and proteomic analysis. With a strong commitment to research and development, Exagen continues to expand its portfolio of diagnostic tools, aiming to address unmet medical needs and revolutionize personalized medicine. With its rich history and expertise in molecular diagnostics, Exagen Inc has established itself as a trusted provider of innovative diagnostic solutions in the healthcare industry.

Exagen Inc has achieved several significant milestones. The company successfully launched its flagship product, AVISE CTD, a comprehensive diagnostic test for autoimmune connective tissue diseases. Exagen Inc also expanded its product portfolio with the addition of AVISE Lupus, a diagnostic test for systemic lupus erythematosus. Furthermore, the company received ISO 13485:2016 certification, demonstrating its commitment to quality management systems. Exagen Inc's advancements in precision medicine and dedication to improving patient outcomes have positioned the company as a leader in the field.

Exagen Inc is primarily present in the United States.

Exagen Inc represents values of innovation, excellence, and patient-centricity. With a commitment to advancing precision medicine, Exagen Inc focuses on transforming the care of patients by providing solutions for complex autoimmune diseases. Their corporate philosophy revolves around developing and commercializing diagnostic tests that empower physicians to deliver personalized treatment plans. Exagen Inc leverages cutting-edge technology and scientific expertise to improve patient outcomes and enhance the overall healthcare experience. By continuously investing in research and development, Exagen Inc aims to revolutionize the diagnosis and management of autoimmune diseases, making a positive impact on the lives of individuals worldwide.

Analysts currently set an average price target of 13,55 USD for the Exagen stock (median: 15,30 USD), implying +103,5 % versus the latest price. The consensus is based on 12 analyst ratings.

Exagen Analyytikkojen kursstavoitteet 2026

12 analysts currently rate the Exagen stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Exagen to generate revenue of 71,59 M USD and earnings per share of −0,58 USD.

Exagen Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Exagen share trades at 5,75 EUR (6,66 USD).

The Exagen share (XGN) is listed on 3 stock exchanges, including: NASDAQ (XGN), Frankfurt (E08A.F), München (E08A.MU).

Exagen Inc is an innovative provider of diagnostic tools and services to support clinics and research institutions in personalizing treatment plans for patients with autoimmune diseases. The company's business model is based on providing top-notch diagnostic solutions and interacting with professionals to ensure optimal patient treatment. The company specializes in the development, manufacturing, and distribution of diagnostic tests to support treatment plans for autoimmune diseases. The tests aim to serve both clinical and scientific purposes by delivering fast, accurate, and predictable results. The company's focus is on expanding the currently limited availability of tests for autoimmune diseases to enable personalized treatment plans for patients. One important area for Exagen Inc is the Clinical Research division. The company offers a range of diagnostic solutions for clinical studies to meet the need for personalized treatment options for patients with autoimmune diseases. The diagnostic tests in clinical studies are based on a thorough analysis of biomarkers characteristic of the disease. Another crucial segment for Exagen Inc is the individual diagnostics segment. The company offers its customers personalized diagnostic solutions for autoimmune diseases to enable tailored treatment for patients. The customizable solutions for autoimmune diseases aim to reduce the burden on patients by performing the appropriate tests, such as lupus, rheumatoid arthritis, or Sjögren's syndrome, for an accurate diagnosis. As part of its business model, Exagen Inc also collaborates with other companies to expand its portfolio of diagnostic solutions. The company maintains relationships with leading research centers and clinics to gain and share valuable insights from practice. Through this collaboration, the company can minimize risks and identify innovative partners. Exagen Inc is constantly striving to expand its range of diagnostic solutions for autoimmune diseases and stay up to date with the latest research in personalized medicine. The company aims to provide patients with autoimmune diseases with fast and accurate diagnoses, as well as suggest personalized treatment options. The company's business model offers an optimized approach to personalized treatment plans and better quality of life for patients with autoimmune diseases. The translation is provided as follows: Exagen Inc is an innovative provider of diagnostic tools and services to support clinics and research institutions in personalizing treatment plans for patients with autoimmune diseases.

odotettu liikevaihto Exagen on 71,59 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Exagen on −12,56 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Exagen:n hinta-voitto-suhde (P/E) on tällä hetkellä −11,43. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Exagen-osakkeen arvostusta.

Exagen:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,01. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Exagen-osakkeen arvostuskennuslukuna.

Exagen:n Eulpool-laatuscore on 4/10.

Exagen:n ISIN on US30068X1037. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Exagen:n WKN on A2PRXT. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Exagen:n ticker on XGN. Tämä pörssinoteeraus käytetään Exagen-osakkeiden kauppaan pörssissä.

Exagen maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Exagen kuuluu sektoriin 'Terveydenhuolto'.

Exagen:n osingot jaetaan valuutassa USD.